MedTrace Logo

Genetic Variability in CYP2D6 in U.S Active Duty Population

NCT02960568 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 550

Last updated 2021-10-20

No results posted yet for this study

Summary

The investigator proposes to 2D6 (Cytochrome P-450 Isoenzyme 2D6) genotype and phenotype a group of active duty service members and assess the effects on primaquine metabolism.

Conditions

  • Pharmacologic Action

Interventions

DRUG

Primaquine

30 mg oral primaquine one time

Sponsors & Collaborators

  • Walter Reed Army Institute of Research (WRAIR)

    lead FED

Principal Investigators

  • Norman Waters, PhD · Walter Reed Army Institute of Research (WRAIR)

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-08
Primary Completion
2017-07-31
Completion
2017-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02960568 on ClinicalTrials.gov